Ped­al to the met­al, Am­gen fi­nal­ly has a hot new drug star on its hands — and they have some news

Once you’ve got some buzz go­ing for a po­ten­tial break­through drug, it doesn’t take much more than a hint of progress to get the in­dus­try spot­light to swiv­el back in your di­rec­tion.

For Am­gen $AMGN, where that kind of R&D ex­cite­ment has been a long time com­ing, their mo­ment ar­rived Tues­day evening, when the phar­ma gi­ant not­ed that they had reg­is­tered widen­ing re­spons­es for their KRAS drug AMG510, adding tu­mor re­spons­es in col­orec­tal and ap­pen­diceal can­cer pa­tients af­ter re­port­ing a 50% re­sponse rate among a tiny group of non-small cell lung can­cer groups at AS­CO.

“We have com­plet­ed en­roll­ment in our monother­a­py ex­pan­sion co­hort and are al­so now en­rolling non-small cell lung can­cer pa­tients in the PD-1 com­bi­na­tion arm,” added R&D chief David Reese in their call with an­a­lysts.

There’s more. From Reese:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER